Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Recruiting
Observational Study
Lynch Syndrome
Lynch Syndrome I
Lynch Syndrome II
Lynch Syndrome I (Site-specific Colonic Cancer)
HNPCC
HNPCC Gene Mutation
Hereditary Cancer Syndrome
Hereditary Cancer
MLH1 Gene Mutation
MLH1 Gene Deletion+Duplication
MLH1 Loss of Expression
MLH1 Gene Inactivation
MSH2 Gene Mutation
MSH2 Gene Deletion+Duplication
MSH2 Loss of Expression
MSH2 Gene Inactivation
MSH6 Gene Mutation
MSH6 Loss of Expression
MSH6 Gene Inactivation
PMS2 Gene Mutation
PMS2 Gene Inactivation
PMS2 Loss of Expression
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- San Raffaele University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lynch syndrome (OMIM #120435) is the most common dominantly inherited colorectal cancer syndrome with an estimated prevalence of 1:270 individuals. It increases the lifetime risk of colorectal and endometrial cancer primarily, but it is associated with a high risk of other cancers (pancreas, stomach, ovarian, central nervous system, skin, among others). It is caused by a germline mutation in one o…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria (for participants with Lynch syndrome):
* Age ≥18 years
* All sexes eligible
* Established diagnosis of Lynch syndrome performed as part of clinical practice, with a germline pathogenic/likely pathogenic variant in one of the following genes: MLH1, MSH2, MSH6, PMS2, and EpCAM
* S…
Contacts